Therapeutic Antibodies – News and Features
News
Protein Design Labs Becomes PDL BioPharma
Protein Design Labs has changed the name to better reflect its status as a commercial company.
News
Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
Roche and Xencor entered into this collaboration in January 2005, in which Roche applies Xencor's XmAb Fc domains.
News
Symphogen’s Success Attracts USD 25 Million Investment
The financing will be used to carry out clinical trials of Symphogen’s first product, anti-RhD.
News
Morphotek Divests Cell Evolution Service Business to Invitrogen
This divestment allows Morphotek to focus its business strategy on advancing its therapeutic antibody pipeline.
News
CoGenesys Licenses Intellectual Property Rights for Target Antigen to PDL
PDL will provide CoGenesys with access to its antibody humanization technology platform.
News
PDL Grants Patent Licenses to Merck for Humanized Antibodies
The licensing of humanized antibody technology will build a commercial operation focused on the acute care hospital setting.
News
Morphotek Expands Oncology Pipeline with Product Candidate from NCI
Morphotek is applying its antibody technologies to develop and optimize antibodies to cancer-associated proteins.
News
Acceptys and OncoMab Announce Integration of Human Antibody Drug Development Pipeline and Operations
Acceptys has acquired the right to develop all 8 lead antibody therapeutic candidates from the OncoMab pipeline.
News
Antibody Therapy Promising for Pediatric Neuroblastoma
Study suggests that the immune system can be manipulated to target cancer cells, resistant to chemotherapy.
News
MorphoSys Signs Agreement for Use of Antibody Technologies with Merck & Co.
The agreement enables Merck to develop HuCAL®-derived therapeutic antibodies in a range of indications.
Advertisement
